Skip to main content
SpringerLink
Log in

Initial evaluation of dynamic human imaging using18F-FRP170 as a new PET tracer for imaging hypoxia

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

18F-FRP170, 1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, is a new hypoxia imaging agent for positron emission tomography. This compound was synthesized by18F-labeling of RP170, which was developed as a new hydrophilic 2-nitroimidazole analog. In the present study, we analyzed dynamic whole-body imaging in healthy volunteers and dynamic tumor imaging in three patients with lung cancer.Methods: Four healthy male volunteers and three lung cancer patients were enrolled in this study. Volunteers underwent dynamic whole-body scans just after injection of18F-FRP170 for about 90 min, while the lung cancer patients underwent dynamic tumor imaging for about 60 or 120 min. Data are expressed as standardized uptake values (SUV). Regions of interest were placed over images of each organ or tumor to generate time-SUV curves.Results: The series of dynamic whole-body scans showed rapid elimination of18F-FRP170 from the kidneys following elimination from the liver. Very low physiological uptake was observed above the diaphragm.18F-FRP170 uptake in the lung cancer lesion could be visualized clearly from early after injection. The changes of tumor SUV, tumor/blood ratio, or tumor/muscle ratio about 30 min after injection or later were small.Conclusions: Dynamic imaging using18F-FRP170 demonstrated rapid elimination from the kidney, suggesting the high hydrophilicity of this imaging agent. The background activity above the diaphragm was very low, and patients with lung cancer showed clear tumor uptake of18F-FRP170 early after injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia.Eur J Nucl Med 1995; 22: 265–280.

    Article  PubMed  CAS  Google Scholar 

  2. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability.Br J Cancer 1981; 43: 546–550.

    PubMed  CAS  Google Scholar 

  3. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.Int J Radiat Oncol Biol Phys 1995; 33: 391–398.

    PubMed  CAS  Google Scholar 

  4. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.Int J Radiat Oncol Biol Phys 1996; 36: 417–428.

    PubMed  CAS  Google Scholar 

  5. Sasai K, Shibamoto Y, Takahashi M, Abe M, Wang J, Zhou L, et al. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.Jpn J Cancer Res 1989; 80: 1113–1118.

    PubMed  CAS  Google Scholar 

  6. Murayama C, Suzuki A, Sato C, Tanabe Y, Miyata Y, Shoji T, et al. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.Int J Radiat Oncol Biol Phys 1992; 22: 557–560.

    PubMed  CAS  Google Scholar 

  7. Murayama C, Suzuki A, Suzuki T, Miyata Y, Sakaguchi M, Tanabe Y, et al. Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170).Int J Radiat Oncol Biol Phys 1989; 17: 575–581.

    PubMed  CAS  Google Scholar 

  8. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE. et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.Radiology 1995; 194: 795–800.

    PubMed  CAS  Google Scholar 

  9. Wada H, Iwata R, Ido T, Takai Y. Synthesis of 1-[2-[18F]fluoro-1-(hydroxymethyl)-ethoxy]methyl-2-nitroimidazole ([18F]FENI), a potential agent for imaging hypoxic tissues by PET.J Label Compd Radiopharm 2000; 43: 785–793.

    Article  CAS  Google Scholar 

  10. Kaneta T, Takai Y, Kagaya Y, Yamane Y, Wada H, Yuki M, et al. Imaging of ischemic but viable myocardium using a new18F-labeled 2-nitroimidazole analog,18F-FRP170.J Nucl Med 2002; 43: 109–116.

    PubMed  CAS  Google Scholar 

  11. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W.Ann Nucl Med 1997; 11: 307–313.

    Article  PubMed  CAS  Google Scholar 

  12. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.Radiat Res 1980; 82: 171–190.

    Article  PubMed  CAS  Google Scholar 

  13. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, et al.In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.Br J Cancer 2004; 90: 2232–2242.

    PubMed  CAS  Google Scholar 

  14. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.J Nucl Med 1999; 40: 1072–1079.

    PubMed  CAS  Google Scholar 

  15. Kumar P, Stypinski D, Xia H, McEwan A, Machulla H, Wiebe LI. Fluoroazomycin arabinoside (FAZA): Synthesis,2H and3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia.J Label Compd Radiopharm 1999; 42: 3–16.

    Article  CAS  Google Scholar 

  16. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with18F-fluoroazomycin arabinoside.J Nucl Med 2005; 46: 106–113.

    PubMed  Google Scholar 

  17. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.J Nucl Med 2005; 46: 253–260.

    PubMed  Google Scholar 

  18. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer.Int J Radiat Oncol Biol Phys 2004; 59: 971–982.

    Article  PubMed  Google Scholar 

  19. Ishikawa Y, Funaki Y, Iwata R, Furumoto S, Nakata E, Kudo Y, et al. [Development of [18F]FRP-170 injection for imaging hypoxia by PET].KAKU IGAKU (Jpn J Nucl Med) 2005; 42: 1–10.

    CAS  Google Scholar 

  20. Graziano MJ, Henck JW, Meierhenry EF, Gough AW. Neurotoxicity of misonidazole in rats following intravenous administration.Pharmacol Res 1996; 33: 307–318.

    Article  PubMed  CAS  Google Scholar 

  21. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas correlation of hypoxia, metabolism and VEGF expression.Eur J Nucl Med Mol Imaging 2003; 30: 695–704.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Tomohiro Kaneta M.D., Ph.D., Takashi Hakamatsuka & Shoki Takahashi

  2. School of Health Sciences, Faculty of Medicine, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Yoshihiro Takai & Eiko Nakata

  3. Cyclotron and Radioisotope Center, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Ren Iwata, Yoichi Ishikawa, Shoichi Watanuki, Shozo Furumoto, Yoshihito Funaki & Masatoshi Ito

  4. Department of Geriatric and Respiratory Medicine, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Hiroyasu Yasuda & Katsutoshi Nakayama

  5. Department of Radiation Oncology, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Keiichi Jingu & Shogo Yamada

  6. POLA Chemical Industries, Yokohama, Japan

    Michihiko Tsujitani

  7. Institute of Development, Aging and Cancer, Tohoku University, 1-1 Seiryomachi, Aoba-ku, 980-8574, Sendai, Japan

    Hiroshi Fukuda

Authors
  1. Tomohiro Kaneta M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ren Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Hakamatsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyasu Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsutoshi Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoichi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shoichi Watanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shozo Furumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshihito Funaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eiko Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keiichi Jingu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michihiko Tsujitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masatoshi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hiroshi Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shoki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Shogo Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomohiro Kaneta M.D., Ph.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaneta, T., Takai, Y., Iwata, R. et al. Initial evaluation of dynamic human imaging using18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 21, 101–107 (2007). https://doi.org/10.1007/BF03033987

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03033987

Key words

Search

Navigation